The use of fibric Acid derivatives in cardiovascular prevention

Area of Science:

• Cardiology
• Pharmacology
• Lipidology

Background:

• Low-density lipoprotein (LDL) cholesterol reduction effectively prevents atherosclerotic cardiovascular disease.
• Residual cardiovascular risk persists despite statin therapy, highlighting the need for additional lipid-modifying strategies.
• Fibrates, known to reduce triglycerides and increase high-density lipoprotein (HDL) cholesterol, have shown mixed results in clinical outcomes trials.

Purpose of the Study:

• To evaluate the role of fibrates in managing dyslipidemia and residual cardiovascular risk.
• To assess the efficacy of fibrates in reducing cardiovascular events, particularly in specific patient subgroups.
• To determine the optimal place of fibrates in the context of statin therapy.

Main Methods:

• Review of clinical trials and meta-analyses on fibrate therapy.
• Analysis of post-hoc data from fibrate outcome trials.
• Examination of fibrate effects on lipid profiles and cardiovascular events.

Main Results:

• Fibrates demonstrated a reduction in primarily non-fatal coronary events, without impacting total mortality.
• Benefits were most pronounced in patients with elevated triglycerides and low HDL cholesterol levels.
• Adding fibrates to statin therapy showed particular benefit in high-risk patients with diabetes or metabolic syndrome.

Conclusions:

• Fibrates are not first-line agents for dyslipidemia but are valuable adjuncts for high-risk patients on statins with persistent atherogenic lipid profiles.
• The primary benefit of fibrates lies in reducing non-fatal coronary events in specific dyslipidemic populations.
• Fibrates play a role in managing complex lipid disorders, especially in conjunction with statins for patients with diabetes or metabolic syndrome.